Sign in

CNTN on Nasdaq

Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc. is an American finance services company that raised $9.6 million in 2025 (SEC Form D).1 It is headquartered in New York, New York.1 Its shares trade on Nasdaq under the symbol CNTN.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerCNTN on Nasdaq1
  • IndustryFinance Services1
  • HeadquartersNew York, New York1
  • Incorporated inDE2
  • Business address1460 Broadway, New York, Ny 100362
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

November 2025, we have strengthened our liquidity and expanded our access to capital through a public offering of common stock and private placements, and by establishing a shelf registration statement and our ATM Program (as defined below).3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$20.1M in 2025+1012% since 2020
-$30.0M-$20.0M-$10.0M02020: -$1.8M-$1.8M20202021: -$3.2M-$3.2M2021+77%2022: -$6.9M-$6.9M2022+115%2023: -$9.5M-$9.5M2023+37%2024: -$12.4M-$12.4M2024+32%2025: -$20.1M-$20.1M2025+62%
Net income45678-$35.9M in 2025+1386% since 2020
-$40.0M-$30.0M-$20.0M-$10.0M02020: -$2.4M-$2.4M20202021: -$2.2M-$2.2M2021−9%2022: -$8.5M-$8.5M2022+284%2023: -$9.3M-$9.3M2023+10%2024: -$12.2M-$12.2M2024+31%2025: -$35.9M-$35.9M2025+194%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
Research and development$3.1M$6.4M
General and administrative$17.0M$6.0M
Total operating expenses$20.1M$12.4M
Loss from operations-$20.1M-$12.4M
Interest expense-$28.3K-$13.7K
Interest income$41.4K$249.9K
Unrealized loss from digital assets holdings-$22.0M
Total other income (expense), net-$22.0M$236.2K
Total loss before income taxes-$42.1M-$12.2M
Provision (benefit) for income taxes-$6.2M
Net loss-$35.9M-$12.2M
Basic-$1.12-$9.41
Diluted-$1.12-$9.41
Basic32.0M shares1.3M shares
Diluted32.0M shares1.3M shares

Compare Canton Strategic Holdings, Inc. with another company

Corporate structure

Canton Strategic Holdings, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Canton Strategic Holdings, Inc.

  • ARK Investment Management LLC Filed SCHEDULE 13G/A on Canton Strategic Holdings, Inc., latest Jul 8, 2026 (2 filings since Feb 3, 2026)
  • LCV FUND VIII, L.P. Filed SCHEDULE 13G/A on Canton Strategic Holdings, Inc., latest May 11, 2026 (2 filings since Feb 2, 2026)
  • Broadridge Financial Solutions Filed SCHEDULE 13G on Canton Strategic Holdings, Inc., latest Feb 6, 2026
  • BlackRock Filed SCHEDULE 13G/A on Canton Strategic Holdings, Inc., latest Jan 21, 2026 (2 filings since Oct 17, 2025)
  • Gravitas Capital LP Filed SCHEDULE 13D on Canton Strategic Holdings, Inc., latest Jun 20, 2025
  • GSB Holdings, Inc. Filed SCHEDULE 13G on Canton Strategic Holdings, Inc., latest May 23, 2025
  • TANG CAPITAL PARTNERS LP Filed SC 13G/A on Canton Strategic Holdings, Inc., latest Feb 14, 2024 (2 filings since Dec 7, 2023)
  • Canton Strategic Holdings, Inc. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Canton Strategic Holdings, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Properties, in its own words

Our executive office, which we lease on a month-to-month basis, is located at 34 Shrewsbury Ave., Suite 1C, Red Bank, New Jersey 07701. We believe that our existing facilities are suitable and adequate to meet our current needs. We intend to add new facilities or expand existing facilities as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led Canton Strategic Holdings, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Randy Milby2022–2025
  2. Sireesh Appajosyula2025
  3. Mark Paul Wendland2025–now

Chair

  1. Vincent S. Lopriore2025–now

President

  1. Mark Christopher Toomey2025–now

Chief financial officer

  1. Jacob Asbury2026–now

Chief operating officer

  1. Sireesh Appajosyula2024–2025
  2. Sanam Parikh2025–2026
  3. Angela Dominy Radkowski2026–now
2025
Board members and other officers (13)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerThomas Hess named Jun 28, 2024 to Dec 17, 202432
  • DirectorClay Kahler named Jul 7, 2025 to Apr 15, 202633
  • DirectorKelly A/ Anderson named Jun 28, 2024 to Dec 17, 202432

Former names

  • Tharimmune, Inc.Sep 25, 2023 to Feb 11, 20262
  • Hillstream BioPharma Inc.May 17, 2021 to Sep 12, 20232

Timeline

  1. Aug 14, 20268-K Results of operations34
  2. Jul 23, 20268-K Entered a material agreement; Completed an acquisition or sale; Other events35
  3. Jul 17, 20268-K Shareholder vote; Other events36
  4. Jun 16, 20268-K Regulation FD disclosure; Other events37
  5. Mar 31, 20268-K Other events38
  6. Mar 3, 20268-K Other events39
  7. Mar 3, 20268-K Entered a material agreement40
  8. Feb 18, 20268-K Bylaws or fiscal year changed; Regulation FD disclosure41
  9. Feb 6, 20268-K Executive or director change; Regulation FD disclosure; Other events42
  10. Feb 2, 20268-K Shareholder vote; Other events43
  11. Jan 26, 20268-K Other events44
  12. Jan 22, 20268-K Entered a material agreement; Other events45
  13. Nov 14, 2025New chief executive Mark Paul Wendland becomes CEO12
  14. Jun 23, 2025New chief executive Sireesh Appajosyula becomes CEO11
  15. Jan 12, 2022New chief executive Randy Milby becomes CEO13

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/202646

When it reported results

  1. Aug 14, 2026Reported quarterly or annual results34

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

298 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 77 major events, 82 insider forms, 11 large holders, 5 private raises, 103 other. The latest 20:

  1. Aug 14, 20268-K EDGAR
  2. Aug 14, 202610-Q EDGAR
  3. Jul 23, 20268-K EDGAR
  4. Jul 17, 20268-K EDGAR
  5. Jul 15, 20263 EDGAR
  6. Jul 15, 20263 EDGAR
  7. Jul 15, 20263 EDGAR
  8. Jul 8, 2026SCHEDULE 13G/A EDGAR
  9. Jun 25, 2026DEF 14A EDGAR
  10. Jun 16, 20268-K EDGAR
  11. May 27, 20264 EDGAR
  12. May 13, 202610-Q EDGAR
  13. May 11, 2026SCHEDULE 13G/A EDGAR
  14. Apr 15, 2026D EDGAR
  15. Apr 15, 2026D EDGAR
  16. Mar 31, 202610-K EDGAR
  17. Mar 31, 20268-K EDGAR
  18. Mar 11, 2026S-8 EDGAR
  19. Mar 3, 20268-K EDGAR
  20. Mar 3, 2026424B5 EDGAR

The 298 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

20 open-market trades by officers, directors and large owners since October 2021: 18 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 26, 2026Stetz Gary S.DirectorSale12,500$3.47$43.4KForm 4
May 22, 2026Stetz Gary S.DirectorSale87,851$3.42$300.5KForm 4
Jun 20, 2025Gravitas Capital LP10% ownerBuy337,838$1.48$500.0KForm 4
Jun 20, 2025Parikh SanamCOOBuy1,000$1.45$1.4KForm 4
Jun 20, 2025Appajosyula SireeshCEOBuy61,496$1.48$91.0KForm 4
May 15, 2025Parikh SanamCOOBuy770$1.30$1.0KForm 4
Dec 19, 2024MILBY RANDYCEOBuy4,600$2.12$9.8KForm 4
Nov 13, 2024Appajosyula SireeshCEOBuy5,000$2.02$10.1KForm 4
Oct 8, 2024MILBY RANDYCEOBuy2,500$2.09$5.2KForm 4
Oct 8, 2024Appajosyula SireeshCEOBuy5,000$1.93$9.7KForm 4
Oct 8, 2024Appajosyula SireeshCEOBuy5,000$1.93$9.7KForm 4
Dec 15, 2023MILBY RANDYCEOBuy29,000$0.50$14.5KForm 4
Nov 30, 2023MILBY RANDYCEOBuy10,000$1.00$10.0KForm 4
Jun 17, 2022MILBY RANDYCEOBuy500$0.78$390Form 4
Jun 6, 2022MILBY RANDYCEOBuy1,000$0.69$687Form 4
Jun 1, 2022MILBY RANDYCEOBuy1$0.94$1Form 4
May 25, 2022MILBY RANDYCEOBuy1,000$0.79$786Form 4
May 20, 2022MILBY RANDYCEOBuy1,000$0.92$920Form 4
May 19, 2022MILBY RANDYCEOBuy1,000$0.91$910Form 4
Jan 14, 2022Mazur Leonard LDirectorBuy25,000$4.00$100.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Sireesh Appajosyula$376.3K$2.9M54
2025Randy Milby$357.5K$618.5K54
2025Mark Wendland47$83.3K$358.3K54
2025Mark Toomey56$83.3K$208.3K54
2025Jacob Asbury53$22.5K$30.2K54
2024Former ChiefExecutive Officer$6$959.3K54
2024Former Interim Chief Financial OfficerChief Operating Officer and Chief Executive Officer$7$700.6K54

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$9.6M 2024–2025
Money received by yearMoney received by year, 2024–2025: $9.6M in all. Private raises (Form D) $9.6M.$0$2M$4M$6M2024 · Private raises (Form D): $4.1M20242025 · Private raises (Form D): $5.5M2025
Figures by year
YearPrivate raises (Form D)Total
2025$5.5M$5.5M
2024$4.1M$4.1M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Jul 25, 2025Raised $1.2 million in a private offering of equity55 Form D: 6 investors so far Form D
  2. Jul 23, 2025Raised $1.7 million in a private offering of equity33 Form D: 13 investors so far Form D
  3. Jun 13, 2025Raised $2.5 million in a private offering of equity56 Form D: 30 investors so far Form D
  4. Dec 9, 2024Raised $2 million in a private offering of equity32 Form D: 7 investors so far Form D
  5. Jun 18, 2024Raised $2.1 million in a private offering of equity57 Form D: 5 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 68. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
ARK Investment Management LLC3,657,548$10.3M0.1%−37,536
BlackRock, Inc.3,643,243$10.3M0.0%+2,877,414
Vanguard Capital Management LLC3,018,785$8.5M0.0%+2,566,105
DRW Securities, LLC1,724,618$4.9M0.3%New
Geode Capital Management, LLC1,422,280$4.0M0.0%+982,168
State Street Corp929,471$2.6M0.0%+727,600
Amova Asset Management Americas, Inc.703,361$2.0M0.0%−24,806
Sumitomo Mitsui Trust Group, Inc.703,361$2.0M0.0%−24,806
Bienville Capital Management, LLC650,407$1.8M0.3%+433,605
Vanguard Fiduciary Trust Co421,745$1.2M0.0%+210,300
Blair William & Co/il384,692$1.1M0.0%+10,000
Northern Trust Corp383,947$1.1M0.0%+297,156
Summit Trail Advisors, LLC309,475$872.7K0.0%+159,698
Vanguard Portfolio Management LLC300,603$847.7K0.0%New
Genesis Financial Group, LLC270,992$764.2K0.5%New
Osaic Holdings, Inc.259,801$732.6K0.0%+70,000
Renaissance Technologies LLC189,628$534.8K0.0%−372,372
Goldman Sachs Group Inc168,034$473.9K0.0%+97,737
Bank of New York Mellon Corp122,283$344.8K0.0%New
Galaxy Digital Capital Management GP LLC116,451$328.4K0.2%New
Zuckerman Investment Group, LLC111,273$313.8K0.0%+64,300
UBS Group AG99,113$279.5K0.0%+52,805
Charles Schwab Investment Management Inc94,221$265.7K0.0%New
Nuveen, LLC59,500$167.8K0.0%New
Van Eck Associates Corp45,704$128.9K0.0%+14,204

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Canton Strategic Holdings, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCanton Strategic Holdings, Inc.1
  • CIK0001861657
  • Employer ID (EIN)84-26425413
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)6199 Finance Services1
  • SEC reviewing officeOffice of Crypto Assets, Division of Corporation Finance1
  • Business address1460 Broadway, New York, NY 100361
  • Phone(212) 210-60061
  • Shares outstanding79,681,361 as of Aug 13, 20269
  • Public float$6.4M as of Jun 30, 20253
  • AuditorRosenberg Rich Baker Berman P.A, Somerset, New Jersey PCAOB ID 89; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMay 17, 20211
  • Filings307 in all: 8-K (75), 4 (49), 3 (29), CORRESP (17), 10-Q (14), 424B5 (10), EFFECT (10), UPLOAD (10)1
    All 40 form types

    DEFA14A (9), S-3 (8), DEF 14A (7), 424B3 (6), S-8 (6), 10-K (5), D (5), S-1/A (5), SCHEDULE 13G (5), PRE 14A (4), FWP (3), SCHEDULE 13G/A (3), 3/A (2), 4/A (2), 8-K/A (2), ARS (2), DRS/A (2), DRSLTR (2), S-1 (2), 10-K/A (1), 424B4 (1), 8-A12B (1), CERT (1), DEL AM (1), DRS (1), NT 10-K (1), NT 10-Q (1), PRER14A (1), S-3/A (1), SC 13G (1), SC 13G/A (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Jun 25, 2026
    Latest 8-K (8-K) Aug 14, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, $0.0001 par valueCNTNThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Canton Strategic Holdings, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 72 risks under these headings, as written.3

  • Risks Related to Our CC Strategy and Holdings
  • We are shifting our business strategy from biotechnology operations to a CC treasury strategy, which represents a fundamental change in our risk profile and may not be successful.
  • We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition, and results of operations.
  • Our digital asset treasury exposure to CC involves novel and significant risks, including market volatility, accounting, regulatory, custody, cybersecurity, liquidity and reputational risks, which could have a material adverse effect on our business, results of operations and financial condition.
  • Failure of the Canton Network to achieve broad market acceptance would materially and adversely affect our business, financial condition, and results of operations.
  • Regulatory change reclassifying CC as a security could lead to our classification as an “investment company” under the Investment Company Act of 1940, as amended, or the 1940 Act, and could adversely affect the market price of CC and the market price of our common stock.
  • Our financial results and the market price of our common stock may be affected by the prices of CC.
  • The concentration of CC ownership could increase the risk of malicious activity, including potential attacks on the Canton Network.
  • We face risks relating to the custody of our CC tokens, including the loss or destruction of private keys required to access our CC tokens and cyberattacks or other data loss relating to our CC tokens, including smart contract related losses and vulnerabilities.
  • We will operate in a highly competitive environment and will compete against companies and other entities with similar strategies, including companies with significant CC holdings and spot exchange traded funds and spot ETPs for digital assets.
  • The availability of spot ETPs for CC and other digital assets may adversely affect the market price of our listed securities.
  • If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain access to our CC, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose some or all of our CC and our financial condition and results of operations could be materially adversely affected.
The other 61 risks
  • We face other risks related to our CC digital asset treasury reserve business model.
  • Negative developments in the cryptocurrency industry — including fraud, cybercrime or platform failures — may result in unfavorable publicity and could impact investor sentiment with respect to us even if we are not directly involved in any of the reported events.
  • Our CC holdings are and will be less liquid than our existing cash and cash equivalents and may not be able to serve as a source of liquidity for us to the same extent as cash and cash equivalents.
  • If we elect to use derivative instruments to hedge the price risk of holding CC, such derivatives are highly volatile and subject to market and liquidity risks, which could negatively impact our digital asset treasury strategy.
  • We will be exposed to the default risk of our clearing broker if we hedge the price risk of CC through the purchase of futures contracts.
  • We face risks relating to the use of third-party exchanges in connection with our CC strategy.
  • Future developments regarding the treatment of crypto assets for U.S. and foreign tax purposes could adversely impact our business.
  • We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers.
  • Risks Related to Our Therapeutic Candidates Developments
  • We are substantially dependent on the success of our product candidates. If we are unable to complete development of, obtain approval for, or successfully commercialize our product candidates, our business may be harmed.
  • Our pipeline is based on novel ideas and technologies that are unproven and may not result in marketable products, which exposes us to unforeseen risks and makes it difficult to predict development timelines, costs, and regulatory approval.
  • Delays, suspension, or termination of clinical trials could limit our ability to commercialize products and affect our business prospects.
  • The outcome of pre-clinical testing and early clinical trials may not be predictive of later success.
  • Interim, topline, and preliminary clinical trial data may change as more patient data becomes available and are subject to audit and verification procedures.
  • Adverse side effects or safety risks could delay or preclude approval, cause us to suspend clinical trials, or result in negative consequences following any marketing approval.
  • We may not achieve our development milestones on our projected timelines.
  • Product liability claims could materially harm our business.
  • Our current and future products may never achieve significant commercial market acceptance.
  • We face significant competition from companies that may develop more effective, safer, or less expensive products.
  • We are subject to healthcare laws and regulations.
  • We may not be able to obtain or maintain Fast Track designation or accelerated approval for our drug candidates.
  • We may not be able to obtain or maintain orphan drug designation or exclusivity for our drug candidates.
  • Breakthrough Therapy designation may not lead to faster development, review, or approval.
  • We rely on third parties to conduct our pre-clinical studies and clinical trials, and their failure to perform could substantially harm our business.
  • We rely on third-party manufacturers for our drug candidates and expect to continue doing so for commercialization.
  • We currently depend on a sole source supplier and manufacturer for the active ingredient in our product candidates and the inability to obtain the active ingredient for our product candidates as required could harm our business.
  • Our failure to find third party collaborators to assist or share in the costs of drug development could materially harm our business, financial condition and results of operations.
  • We may not be successful in commercializing one or more of our drug candidates.
  • If we are unable to develop satisfactory sales and marketing capabilities, we may not succeed in commercializing our drug candidates.
  • The development and commercialization of pharmaceutical products are subject to extensive regulation, and we may not obtain regulatory approvals for our drug candidates on a timely basis, or at all.
  • Failure to obtain marketing approval in foreign jurisdictions would prevent our drug candidates from being marketed abroad.
  • Any approved drug candidates may be subject to post-marketing requirements, restrictions, or withdrawal, and noncompliance could result in penalties.
  • Healthcare reform initiatives in the United States may impact our business and results of operations.
  • If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.
  • If we do not obtain patent term extension for any drug candidates we may develop, our business may be materially harmed.
  • Risks Related to Our Operations and Financial Conditions
  • We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.
  • Due to our limited operating history and the concentration of our CC token holdings, it will be difficult to evaluate our business and future prospects, and we may not be able to achieve or maintain profitability in any given period.
  • We will need additional financing in the future, which may not be available when needed or may be costly and dilutive.
  • Our senior management team has limited experience managing and operating a U.S. public company.
  • Unrealized fair value gains on the Company’s CC holdings may cause the Company to become subject to the corporate alternative minimum tax under the Inflation Reduction Act of 2022.
  • Risks Related to Cybersecurity, Information Technology, and Intellectual Property
  • If we or our third-party service providers experience a security breach or cyberattack and unauthorized parties obtain access to our CC tokens, or if our private keys are lost or destroyed, or other similar circumstances or events occur, we may lose some or all of our CC tokens and our financial condition and results of operations could be materially adversely affected.
  • Our business and operations would be adversely impacted in the event of a failure or interruption of our information technology infrastructure or as a result of a cybersecurity attack.
  • Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our drugs.
  • We or our licensors may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.
  • Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.
  • Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
  • If we fail to comply with our obligations in license arrangements with third parties, we could lose rights that are important to our business.
  • If we are unable to obtain licenses from third parties on commercially reasonable terms or at all, our business could be harmed.
  • We may not be able to protect our intellectual property and proprietary rights.
  • Risks Related to Our Securities and Being a Public Company
  • The price of our stock may be volatile, and you could lose all or part of your investment.
  • Sales of our common stock, or the perception that such sales may occur, could cause the market price of our common stock to fall.
  • We have issued warrants exercisable for our securities, which if exercised, would increase the number of shares eligible for future resale in the public market and result in dilution to our stockholders.
  • We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
  • Our Certificate of Incorporation, as amended (“Certificate of Incorporation”) provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between the Company and its stockholders, which could limit stockholders’ ability to obtain a favorable judicial forum for disputes with the Company or its directors, officers or employees.
  • Our Certificate of Incorporation, Bylaws and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.
  • Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price.
  • Market and economic conditions may negatively impact our business, financial condition and share price.
  • We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.
  • Financial reporting obligations of being a public company in the U.S. are expensive and time-consuming, and our management will be required to devote substantial time to compliance matters.
  • If we fail to maintain an effective system of internal controls, we may not be able to accurately determine our financial results or prevent fraud. As a result, our stockholders could lose confidence in our financial results, which could harm our business and the value of our common stock.
  • If securities or industry analysts do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading volume may decline.
  • We could be subject to securities class action litigation.

Legal proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating results.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57